| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial.
|
J Clin Oncol
|
2013
|
3.24
|
|
2
|
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial.
|
Lancet Oncol
|
2013
|
3.24
|
|
3
|
Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial.
|
J Clin Oncol
|
2010
|
2.83
|
|
4
|
Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
|
J Natl Cancer Inst
|
2008
|
1.95
|
|
5
|
A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens.
|
Invest New Drugs
|
2010
|
1.62
|
|
6
|
Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study.
|
Lancet Oncol
|
2011
|
1.59
|
|
7
|
Analysis of regional timelines to set up a global phase III clinical trial in breast cancer: the adjuvant lapatinib and/or trastuzumab treatment optimization experience.
|
Oncologist
|
2013
|
1.29
|
|
8
|
A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.
|
Eur J Cancer
|
2013
|
0.92
|
|
9
|
Genetic changes of p53, K-ras, and microsatellite instability in gallbladder carcinoma in high-incidence areas of Japan and Hungary.
|
World J Gastroenterol
|
2008
|
0.87
|
|
10
|
A case-control study of gallbladder cancer in hungary.
|
Asian Pac J Cancer Prev
|
2009
|
0.78
|
|
11
|
Expert opinion 2011 on the use of new anti-resorptive agents in the prevention of skeletal-related events in metastatic bone disease.
|
Wien Klin Wochenschr
|
2013
|
0.76
|
|
12
|
Effect of genetic predisposition on the risk of gallbladder cancer in Hungary.
|
Asian Pac J Cancer Prev
|
2008
|
0.76
|
|
13
|
Radio-guided resection of non-palpable rectal carcinoma following polypectomy.
|
Hepatogastroenterology
|
2007
|
0.75
|